What is/are Sevelamer?
Sevelamer (rINN) (/sɛˈvɛləmər/ or /sɛˈvɛləmɪər/) is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease. When taken with meals, it binds to dietary phosphate and prevents its absorption. It is marketed by Genzyme (now Sanofi-Aventis) under the trade names Renagel (sevelamer hydrochloride) and Renvela (sevelamer carbonate).
Sevelamer is indicated for the management of hyperphosphataemia in adult patients with stage 4 and 5 chronic kidney disease on hemodialysis.
Sevelamer therapy is contraindicated in hypophosphataemia or bowel obstruction.
Common adverse drug reactions (ADRs) associated with the use of sevelamer include: hypotension, hypertension, nausea and vomiting, dyspepsia, diarrhea, flatulence, and/or constipation.
Sevelamer can significantly reduce serum uric acid. This reduction has no known detrimental effect and several beneficial effects, including reducing hyperuricemia, uric acid nephrolithiasis, and gout.
This article uses material from the Wikipedia article Sevelamer, which is released under the Creative Commons Attribution-Share-Alike License 3.0.